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Abstract
Background: Many potassium ion (K
+) channels function as oncogenes to sustain growth of solid tumors, but
their role in cancer progression is not well understood. Emerging evidence suggests that the early progenitor
cancer cell subpopulation, termed tumor initiating cells (TIC), are critical to cancer progression.
Results: A non-selective antagonist of multiple types of K
+ channels, tetraethylammonium (TEA), was found to
suppress colony formation in endometrial cancer cells via inhibition of putative TIC. The data also indicated that
withdrawal of TEA results in a significant enhancement of tumorigenesis. When the TIC-enriched subpopulation
was isolated from the endometrial cancer cells, TEA was also found to inhibit growth in vitro.
Conclusions: These studies suggest that the activity of potassium channels significantly contributes to the
progression of endometrial tumors, and the antagonists of potassium channels are candidate anti-cancer drugs to
specifically target tumor initiating cells in endometrial cancer therapy.
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Introduction
Potassium (K
+) ion channels are important contributors
to the malignant phenotype in cancer cells and as such
have been shown to drive progression of cancers of the
breast, prostate, endometrium and brain [1-8]. Multiple
mechanisms exist by which K
+ channels exert their
oncogenic functions. For example, K
+ channels have
been shown to modulate cell cycle progression to
increase cell proliferation as well as promote cytoskeletal
remodeling to enhance invasion and migration [9-21].
Inhibitors of K
+ channels thus constitute putative anti-
cancer drugs [1,2,22-26], though to date none of these
antagonists have been explored in a clinical trial setting
for any type of cancer.
Novel developments in cancer research demonstrate
that tumor initiating cells (TIC, also referred to as can-
cer stem cells) cause the onset and recurrence of can-
cers [27-29]. Several biological agents that aim to
eradicate TIC are currently in phase I/II clinical trials,
but a clinical need remains to identify other
pharmacologic approaches to prevent TIC-mediated
tumorigenesis.
Interestingly, K
+ channels genes have been shown to
be amplified in cancers, but the roles of K
+ channels in
TIC and by extension in cancer progression have not
been rigorously addressed. In this manuscript, we pre-
sent novel observations that an inhibitor of multiple
types of K
+ channels, tetraethylammonium (TEA), abro-
gates the tumorigenic abilities of a TIC-enriched subpo-
pulation derived from human endometrial cancer cells
and thus may represent a therapeutic strategy for endo-
metrial cancer therapy.
Results and Discussion
Earlier studies have suggested that, in certain cancers, K
+ channels accelerate tumor growth; however, their role
in the cancer progression remains unclear [1]. Herein,
we examined the importance of the integrated activity
of multiple K
+ channels in the establishment of new
endometrial tumors and their putative roles in the onset
or recurrence of the disease. Cells used in these studies
model two clinically relevant types of endometrial can-
cers: 1) Ishikawa H cells represent a hormone-depen-
dent type (i.e., ER- and PR-positive); and 2) Hec50co
cells are a model of a hormone-independent type (i.e.,
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+ channels as diverse as vol-
tage-gated (e.g., HERG) and calcium-sensitive (e.g.,
IKCa) have been reported to regulate the progression of
endometrial cancers [31,32]. Therefore, we utilized tetra-
ethylammonium (TEA), a broad inhibitor of many types
of K
+ channels, instead of siRNA-mediated silencing of
individual K
+ channels to examine the general integrated
role of voltage-gated, calcium-sensitive, and ATP-sensi-
tive K
+ channels in tumorigenesis.
Earlier reports have documented the growth-promot-
ing effects of K
+ channels in tumors of various origins
[4,14,15]. We therefore hypothesized that cells pre-trea-
ted with an inhibitor of K
+ channels will form fewer
colonies in soft agar. Since most anti-cancer therapies
are acute and not chronic treatment regimens, we first
examined how transient exposure to TEA alters the sub-
sequent ability of endometrial cancer cells to form new
colonies in the absence of TEA. Endometrial cancer
cells pre-treated with TEA for 48 h had no difference in
viability as compared to untreated cells as determined
by trypan blue exclusion (data not shown). Next, endo-
metrial cancer cells were pre-treated with TEA, seeded
onto TEA-free soft agar, and cell colonies visualized by
crystal violet staining three weeks after seeding (Figure
1A). Unexpectedly, Ishikawa H cells pre-treated with
TEA (Figure 1A, Ishikawa H cells, PRE,s h a d e db a r )
exhibited an increased efficiency in formation of new
colonies when compared to the untreated controls (Fig-
ure 1A, Ishikawa H cells, UN, solid bar). Similarly, trea-
ted Hec50co cells (Figure 1A, Hec50co cells, PRE,
shaded bar) showed augmented numbers of colonies in
contrast to the untreated cells (Figure 1A, Ishikawa H
cells, UN, solid bar). These findings indicate that an
enhancement of a tumorigenic ability occurs following a
transient exposure and/or subsequent withdrawal of
TEA.
Since newly arising primary and metastatic tumors are
thought to reflect the presence of TIC [28,29,33], we
hypothesized that the observed potentiation of tumori-
genicity is due to activation of TIC in our cell models.
Therefore, we isolated TIC-enriched subsets from the
Ishikawa H and Hec50co cells to examine whether TEA
regulates these sub-populations. Identification of the
T I Cs u b p o p u l a t i o nf r o mo t h e rc a n c e rc e l lt y p e si sc h a l -
lenging due to their rarity and uncertainties as to TIC-
specific markers. It has been suggested that one differ-
ence between TIC and other cancer cells is a lower rate
of cell division and an elevated activity of the enzyme
aldehyde dehydrogenase isoform 1 (ALDH1)
[28,29,33-35]. We utilized both of these properties to
identify and isolate the TIC-enriched subpopulation
from Ishikawa H and Hec50co endometrial cancer cells.
First, we isolated the cells with high ALDH1 activity,
ALDH1 (+), and compared their tumorigenic capacity to
those with low ALDH1 activity, ALDH1 (-), using mouse
xenograft models. Cells with either high or low ALDH1
activity, as determined by ALDEFLUOR assays, were
injected into the flanks of nude mice and tumor growth
measured 45-60 days later. Figure 1B shows a tumor in
the flank of a mouse where 100,000 ALDH1 positive
Hec50co cells have been injected (Figure 1B, ALDH1
(+)). In contrast, no tumor formed in the opposite flank
that was injected with 100,000 cells with low ALDH1
activity (Figure 1B, ALDH1 (-)). We thus concluded that
a population of TIC is present in our cell models and
they can be identified by the high activity of ALDH1
enzyme.
It has been suggested that not only TIC themselves
but their early progeny also can demonstrate high
ALDH1 activity. As a consequence, ALDH1 positive
cells contain two sub-populations: (1) the rapidly pro-
liferating early progenitor cells; and (2) TIC with a
stem cell-like low proliferation rate or quiescent TIC.
Our subsequent approaches therefore were to differ-
entiate TIC in our cell models on the basis of their
low proliferative rate in addition to the high ALDH1
activity. Specifically, we visualized potential TIC using
a fluorescent cell membrane marker, PKH26, that is
incorporated into the living cells. Retention of PKH26
dye in cell membranes is a function of cell division,
whereby the more times cells divide, the less dye each
cell retains [33,36]. For these studies, we used a modi-
fied clonogenic assay (endosphere culture, see Meth-
ods), and we expected that we could use PKH26
fluorescence intensity to differentiate between the pro-
liferating progenitor cells and the slowly dividing or
quiescent TIC in endospheres. Here we present images
of live Ishikawa H and Hec50co endospheres. The left
panel in Figure 1C is a 3-dimensional reconstruction
of an Ishikawa H endosphere (Figure 1C, left panel,
n u c l e i ,g r e e n )w h e r eo n l yaf e wc e l l s ,p r e s u m e dt ob e
TIC (indicated by the white arrows), show high reten-
tion of a PKH26 dye (Figure 1C, left panel,P K H 2 6 ,
red). This endosphere was additionally visualized using
a transmitted light (Figure 1C, left panel,D I C ,g r e y )
and subsequently all images were merged (Figure 1C,
left panel,m e r g e ,w h i t ea r r o w sp o i n ta tp u t a t i v eT I C ) .
In Hec50co endospheres, (Figure 1C, right panel,
nuclei, green) we observed similar distribution of
PKH26 dye (Figure 1C, right panel, PKH26, red) where
white arrows indicate putative TIC. The fluorescent
and transmitted light (Figure 1C, right panel,D I C ,
grey) images were merged (Figure 1C, left panel,
merge, white arrows designate TIC). We thus con-
cluded that putative TIC are present in our cell models
and can be identified by the high activity of ALDH1
enzyme. Importantly, these cells may be the originators
of new tumor spheres.
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for simultaneous high ALDH1 activity and high reten-
tion of PKH26 dye provides a better phenotypic marker
for TIC than isolating cells using either marker alone.
Therefore, we used this strategy to isolate TIC-enriched
subpopulation and examined the effects of TEA in col-
ony formation of double (PKH26/ALDH1) positive
Ishikawa H and Hec50co cells. First, we treated cells
with 10 μm o l / Lo fT E Af o r4 8h ,a n dt h e ni s o l a t e dt h e
double positive cells via fluorescent cell sorting. As
demonstrated in Figure 2A, we were able to obtain a
population of cells that were positive for both PKH26
and ALDH1. The gated cells were used for subsequent
experiments.
Figure 1 Presence of TIC subpopulation in endometrial cancer cells. (A) Ishikawa H cells untreated (Ishikawa H, solid bar) or pre-treated with
TEA (Ishikawa H, shaded bar) were seeded onto TEA-free soft agar and cell colonies were counted 21 days later. Similarly, Hec50co cells
untreated (Hec50co, solid bar) or pre-incubated with TEA (Hec50co, shaded bar) were grown in TEA-free agar for 21 days. p ≤ 0.05 vs. untreated
for respective cell line; N = 3. (B) Hec50co cells were separated into the sub-populations with high (ALDH1 (+)) and low (ALDH1 (-)) activity of the
enzyme ALDH1 via fluorescent cell sorting. Athymic mice were injected with 100,000 ALDH1(+) or ALDH1(-) cells and inspected for tumor
growth. N = 2. (C) Ishikawa H endospheres (left panel,) and Hec50co endospheres (right panel) were cultured in the presence of a cell membrane
marker PKH26 (red) and counter-stained with the live cell DNA marker CYTO16 (green). Visualization and a three dimensional reconstruction of
images were performed using a Zeiss LSM 510 confocal imaging system. N = 5 (Ishikawa H) and N = 8 (Hec50co).
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Page 3 of 7Figure 2 Effect of TEA on tumorigenic potential of TIC. (A) Ishikawa H (upper panels) or Hec50co (lower panels) cells were propagated in
the presence of a cell membrane marker PKH26 and either kept untreated (left panels) or treated with TEA (right panels). PKH26(+) cells were
isolated, and then ALDH1(+) cells obtained from that population by fluorescent cell sorting. Cells in the box in the right of the plots were
collected for the soft agar assay in Figure 2B. N = 3. (B) Ishikawa H cells untreated (Ishikawa H ALDH1/PKH26(+), UN, solid bar) or pre-treated with
TEA (Ishikawa H ALDH1/PKH26(+), PRE, shaded bar, p ≤ 0.05) were separated by the fluorescent cell sorting. ALDH1/PKH26 positive fractions were
seeded onto the TEA-free soft agar and colonies counted 21 days later. Similarly, Hec50co cells untreated (Hec50co ALDH1/PKH26(+), UN, solid
bar) or pre-incubated with TEA (Hec50co ALDH1/PKH26(+), PRE, shaded bar, p ≤ 0.05) were grown in TEA-free agar for 21 days. N = 4. (C)
Untreated Ishikawa H cells with high PKH26/ALDH1 levels were seeded onto the unaltered soft agar (Ishikawa H, ALDH1/PKH26(+), UN, solid bar)
or on agar supplemented with TEA (Ishikawa H, , ALDH1/PKH26(+), TEA, shaded bar, p ≤ 0.05) and inspected 21 days later. Similarly, PKH26/
ALDH1-positive Hec50co cells on untreated agar (Hec50co, ALDH1/PKH26(+), UN, solid bar) or agar supplemented with TEA (Hec50co, ALDH1/
PKH26(+), TEA, no bar) were counted 21 days later. N = 3.
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sustained exposure to TEA affects formation of new
colonies/tumors. Due to the neurotoxicity of TEA, we
could not utilize mouse xenograft models to test this
hypothesis. We therefore examined growth of cell colo-
nies in soft agar supplemented with 10 μmol/L of TEA
instead. As we expected, double positive Ishikawa H and
Hec50co cells developed colonies in TEA-free agar (Fig-
ure 2C, filled bars). As compared to the untreated coun-
terparts, fewer Ishikawa H colonies grew in TEA-
supplemented agar (Figure 2C, Ishikawa H, shaded bar),
thus demonstrating that continuous exposure to TEA
attenuated the tumorigenic ability of these cells.
Remarkably, TEA completely abolished growth of
Hec50co colonies (Figure 2C, Hec50co). We thus con-
cluded that TEA abrogated the tumorigenic capacity of
Ishikawa H and Hec50co cells, and the TEA withdrawal
observed in Figure 1A results in augmentation of
tumorigenicity.
These findings are significant for several reasons. First,
they validate K
+ channels as candidate anti-cancer tar-
gets to maintain quiescence of TIC. In particular, cancer
patients in remission that have high risk of recurrence
may benefit from such therapy to prolong disease-free
survival. Importantly, other inhibitors that, similar to
TEA, non-selectively antagonize K
+ channels are FDA-
approved to treat human conditions not related to can-
cer. These drugs may possess therapeutic benefits of
TEA without the associated neurotoxicity [37]. Second,
many clinically approved anti-cancer drugs may have
off-target TEA-like inhibitory actions towards the variety
of K
+ channels. Termination of therapy with these drugs
m a yl a yt h ef o u n d a t i o nf o rc a n c e rr e c u r r e n c eb yv i r t u e
of enhancing the tumorigenicity of surviving TIC [37].
Intriguingly, these responses are analogous in ER-, PR-
positive Ishikawa H cells and ER-, PR-negative Hec50co
cells, implying a common response in molecularly dispa-
rate endometrial cancers [30]. The mechanisms whereby
TEA regulates TIC function require further research,
but may involve inhibitor-induced depolarization of
plasmalemmal and/or mitochondrial membranes and
subsequent changes in cell cycle [14]. Also, the contri-
bution of two-pore leak K+ channels, including the K2P
family, to TIC function remains undetermined since
TEA does not inhibit these channels.
Conclusions
In this study, we demonstrate that TEA, an inhibitor of
K
+ channels, decreased tumorigenicity of human endo-
metrial cancer cells. Importantly, withdrawal of TEA led
to a significant potentiation of tumorigenic ability. Our
data suggest that TEA alters tumorigenicity by inhibiting
growth of TIC-enriched subpopulations with high activ-
ity of ALDH1 and a low basal proliferation rate.
Materials and Methods
Reagents
Tetraethylammonium chloride (TEA), crystal violet,
laminin, Dulbecco’s Modified Eagle Medium (DMEM):
F12, gentamicin, PKH26 dye and Triton-X 100 were
purchased from Sigma (St Louis, MO). ALDEFLUOR
assays were from StemCell Technologies (Vancouver,
BC, Canada). Agar, Hoechst 33258 and SYTO 16 were
from Invitrogen (Carlsbad, CA), FBS and 0.25% trypsin/
EDTA from Gibco-BRL (Carlsbad, CA). Low adherence
tissue culture flasks were from A. Daigger&Company
(Vernon Hills, IL) and glass bottom dishes were from
MatTek Corp. (Ashland, MA).
Cell lines
Ishikawa H cells were a generous gift from Dr. Erlio Gur-
pide (New York University). Hec50co cells were devel-
oped in our laboratory from parental Hec50 cells also
kindly provided by Dr. Gurpide [30]. Cells were main-
tained in DMEM:F12 medium supplemented with 20%
fetal bovine serum (FBS) and 50 μg/ml gentamicin. Anti-
biotic-free medium was used for the duration of experi-
ments starting at least 24 h before experimentation.
TEA incubations
Cells were seeded at 100,000 cells per well in 6-well
cluster plates and incubated with 10
-5 mol/L of TEA for
48 h. Subsequently, cells were trypsinized and counted
using Countess Automated Cell Counter (Invitrogen,
Carlsbad, CA). Viability was determined by the trypan
blue exclusion.
ALDH1 activity assays
Aldehyde dehydrogenase isoform 1 (ALDH1) activity
was assayed using ALDEFLUOR kit according to the
manufacturer’s instructions. Briefly, an ALDEFLUOR
reagent was added to the cells. An aliquot of these cells
was removed and. an ALDEFLUOR inhibitor was added
to that to serve as a control for background fluores-
cence. Cells were incubated at 37°C for 40 min and
separated into two sub-populations based on fluores-
cence intensity (highest ALDH1 activity, ALDH1(+);
lowest ALDH1 activity, ALDH1(-)) using a 488 nm laser
(FACS ARIA II, Becton Dickinson, Franklin Lakes, NJ).
Xenograft models
Athymic NCr-nu/nu mice were purchased from NCI at
Frederick (Frederick, MD). Mice were maintained in a
sterile environment according to guidelines established
by the US Department of Agriculture and the American
Association for Accreditation of Laboratory Animal
Care (AAALAC). Cells were assesses for viability using
Hoechst 33258 dye and mice were injected in one flank
with 100,000 ALDH1(+) cells and an equal amount of
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monitored for 6-8 weeks. Two mice were used per cell
line. All procedures were approved by the Institutional
Animal Care and Use Committee at University of Iowa
and complied with the standards stated in the Guide for
the Care and Use of Laboratory Animals.
PKH26 staining
Cell membrane staining with the fluorescent dye PKH26
was performed according to the manufacturer’s instruc-
tions. Briefly, 10
6 cells were re-suspended in 2 mL of
reagent buffer and incubated with 1 μL of PKH26. Sub-
sequently, cells were repeatedly washed, seeded onto the
tissue culture flasks and propagated for at least 7 days
before experimentation.
Fluorescent cell sorting of PKH26/ALDH1 cells
C e l l sw e r es t a i n e dw i t ht h eP K H 2 6d y ef o r7d a y s ,
assayed for ALDH1 activity using ALDEFLUOR reagent,
and immediately analyzed by flow cytometry using 488
nm/561 nm lasers of FACS ARIA II. First, we obtained
a PKH26(+) population of cells, which was then sorted
to obtain ALDH1(+) cells. Cells with the highest levels
of both PKH26 and ALDH1 were used in subsequent
experiments.
Endosphere cultures and imaging
Ishikawa H cells or Hec50co cells stained with PKH26
dye were seeded onto the low adherence tissue culture
flasks in DMEM:F12 medium supplemented with 1%
FBS. Floating cell spheres were examined 7-10 day later
by confocal microscopy. Aliquots of endospheres were
transferred onto 35 mm glass bottom dishes pre-coated
with mouse laminin. Live cell nuclei were counter-
stained with SYTO16 according to the manufacturer’s
instructions and individual spheres were imaged as
stacks of 0.7-1 μm optical slices using 488 nm/561 nm
lasers of a LSM 510 laser confocal microscope (Zeiss,
Jena, Germany). Subsequently, optical slices were recon-
structed into the three dimensional images using LSM
Image Browser (Zeiss, Jena, Germany).
Soft agar assays
Assays were performed in 6-well cluster tissue culture
plates pre-coated with 0.5% basal agar in DMEM:F12.
Cells were over-laid onto the basal agar at 1000 cells
per well in DMEM:F12 supplemented with 0.3% agar
and 20% FBS. Additionally, where indicated, 10
-5 mol/L
TEA was incorporated into the cell suspension. The cell
colonies (50 cells or more) were visualized 21 days later
using crystal violet solution (crystal violet 0.005% and
citric acid 0.1%) and counted.
Statistical analysis
Data was plotted using SigmaPlot 11.0 software (Systat
Software, Inc., San Jose, CA). Statistical significance was
determined by one-way analysis of variance (ANOVA)
and the post hoc Bonferroni’st - t e s t .Ap value <0.05
was considered statistically significant.
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